Menu Search
Equities

Haleon PLC

HLN:LSE

Haleon PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)389.40
  • Today's Change-1.60 / -0.41%
  • Shares traded27.10m
  • 1 Year change+16.38%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 16:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy5
Outperform6
Hold6
Sell1
Strong Sell0

Share price forecast in GBX

The 16 analysts offering 12 month price targets for Haleon PLC have a median target of 400.00, with a high estimate of 450.00 and a low estimate of 330.00. The median estimate represents a 2.30% increase from the last price of 391.00.
High15.6%450.00
Med2.7%400.00
Low-15.3%330.00

Dividends in GBX

In 2023, Haleon PLC reported a dividend of 0.06 GBP, which represents a 150.00% increase over last year. The 18 analysts covering the company expect dividends of 0.06 GBP for the upcoming fiscal year, an increase of 3.33%.
Div growth (TTM)150.00%
More ▼

Earnings history & estimates in GBX

On Aug 01, 2024, Haleon PLC reported 2nd quarter 2024 earnings of 3.84 per share. This result exceeded the 3.64 consensus of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 6.26%.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+9.11%
Haleon PLC reported annual 2023 earnings of 17.30 per share on Feb 29, 2024.
Average growth rate-5.98%
More ▼

Revenue history & estimates in GBP

Haleon PLC had 2nd quarter 2024 revenues of 2.78bn. This bettered the 2.76bn consensus of the 3 analysts covering the company. This was 7.07% below the prior year's 2nd quarter results.
Average growth rate+0.28%
Haleon PLC had revenues for the full year 2023 of 11.30bn. This was 4.09% above the prior year's results.
Average growth rate+4.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.